Fundraising to bolster its positioning
Destiny have announced a conditional fundraising at 50p per share that includes a placing,...
Read moreStrong outlook in uncertain times
Benchmark’s recent Q1 FY22 results highlighted strong operating trends in its three business areas...
Read moreMilestones passed
Despite macro uncertainties, the sharp decline in the share price of Strix over the last six months...
Read more
Q3 trading update underpins forecasts
The group’s Q3 update (to end January 2022) confirmed that underlying trading was broadly in line...
Read more
A flurry of good news
The combined trading and strategic update from Northbridge reports progress across several areas....
Read moreUPGS on track to scale new revenue heights
UPGS’s achievement of 13.7% revenue growth in the first half of FY2022 and anticipation of full...
Read moreVery welcome regulatory clarity
Destiny Pharma has announced details of positive feedback from the European Medicines Agency (EMA)...
Read more'Transformational’ FY21 results
It is worth reiterating the huge scale of the market opportunity Arqit Quantum addresses....
Read more
Register to be first
Get research on the companies that interest you straight to your inbox
